Thymosin Alpha-1
Thymosin Alpha-1 — clinically validated thymic peptide that activates innate and adaptive immunity, approved in 35+ countries for viral infections and immune deficiency.
- Activates dendritic cells and NK cells — the first line of innate immune defence
- Enhances antigen presentation and adaptive T-cell responses
- Clinically approved for hepatitis B, hepatitis C, and COVID-19 in multiple countries
- Anti-cancer immune support — augments checkpoint inhibitor efficacy in trials
- Reduces post-illness immune dysregulation and chronic fatigue patterns
Dosage Calculator
Reference dosing by experience level. For research use only — always consult a licensed healthcare provider.
⚠ For research reference only. Thymosin Alpha-1 is not approved for human use. Always consult a qualified healthcare professional.
What's in the Box
Every Poptides order arrives in premium packaging, ready to use.
Thymosin Alpha-1 Vial
Your selected amount of lyophilized Thymosin Alpha-1 in a sealed, sterile glass vial with silver crimp cap. COA included on request.
BAC Water 3mL
Bacteriostatic water for reconstitution, included with every injectable peptide order. Maintains sterility for multi-dose use.
Syringe Kit
5 × insulin syringes with orange caps, individually sealed, in a dedicated Poptides-branded box.
Research Guide Card + Thank You Note
A QR code card linking to your product's research guide, plus a personal thank you note from the Poptides team.
Discreet Outer Packaging
All orders ship in plain, unmarked outer packaging with no reference to Poptides on the exterior.
How Thymosin Alpha-1 Works
The mechanism of action, step by step.
Dendritic Cell Activation
Thymosin alpha-1 directly activates plasmacytoid and myeloid dendritic cells via toll-like receptor 9, upregulating type I interferon production and initiating rapid pathogen-sensing cascades critical to early immune defence.
T-Cell Maturation and Differentiation
TA-1 promotes the maturation of immature thymocytes into functional Th1 effector cells, increasing IFN-gamma and IL-2 production — the cytokines responsible for directing CD8+ cytotoxic T-cell responses against infected and cancerous cells.
NK Cell Potentiation
TA-1 enhances Natural Killer cell proliferation and cytotoxic capacity, increasing the surveillance and elimination of virally infected cells and tumour targets without requiring prior antigen sensitisation.
TLR-9 / mTOR Pathway Engagement
TA-1 activates mTOR signalling in immune cells via TLR-9, increasing cellular metabolic activity and enabling the rapid proliferation needed to mount an effective adaptive response at the peak of an immune challenge.
Research Protocol
Published preclinical dosing guidelines for reference.
The Science Behind It
Peer-reviewed research supporting the mechanism of Thymosin Alpha-1.
Thymosin alpha-1 for treatment of hepatitis B — multicentre RCT
Thymosin alpha-1 at 1.6 mg twice weekly for 12 months produced significantly higher HBeAg seroconversion and sustained viral response rates compared to placebo in chronic hepatitis B patients, with an excellent safety profile.
Hepatology, 1996Thymosin alpha-1 in COVID-19 — immune modulation and mortality reduction
In severe COVID-19 patients, thymosin alpha-1 administration significantly reduced 28-day mortality, restored CD4+/CD8+ lymphocyte ratios, and dampened hyperinflammatory cytokine storm markers versus standard care alone.
Journal of Infectious Diseases, 2020TA-1 augments anti-tumour immunity and checkpoint inhibitor efficacy
Combination of thymosin alpha-1 with PD-1 checkpoint blockade significantly increased tumour-infiltrating lymphocyte density and extended progression-free survival in murine models of lung and colorectal cancer.
Cancer Immunology Research, 2019Customer Reviews
Verified purchases from Canadian customers.
Dramatically shorter recovery when sick
Added TA-1 to my protocol a year ago. Since then when I do catch something I am over it in 2-3 days versus the 7-10 days I used to be out. The acute protocol at first symptom is incredibly effective.
Remarkable compound with real clinical backing
Unlike many peptides this one has actual phase 3 trial data and regulatory approval in 35 countries. That gave me confidence. My NK cell activity doubled in 8 weeks on the twice-weekly protocol.
Immune support for a compromised patient
Using this under physician guidance for post-cancer immune support. T-cell panels are moving in the right direction and I feel significantly less susceptible to secondary infections.
Frequently Asked Questions
You May Also Like
Thymosin Alpha-1